23 / 72
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 2, March/April 2016
AFRICA
77
20. Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CW. Trophoblast
deportation and the maternal inflammatory response in pre-eclampsia.
J Reprod Immunol
2003;
59
(2): 153–160.
21. Germain SJ, Sacks GP, Sooranna SR, Sargent IL, Redman CW.
Systemic inflammatory priming in normal pregnancy and preeclampsia:
the role of circulating syncytiotrophoblast microparticles.
J Immunol
2007;
178
(9): 5949–5956.
22. Tannetta DS, Dragovic RA, Gardiner C, Redman CW, Sargent IL.
Characterisation of syncytiotrophoblast vesicles in normal pregnancy
and pre-eclampsia: expression of Flt-1 and endoglin.
PLoS One
2013;
8
(2): e56754.
23. Staff AC, Johnsen GM, Dechend R, Redman CW. Preeclampsia and
uteroplacental acute atherosis: immune and inflammatory factors.
J
Reprod Immunol
2014;
101–102
: 120–126.
24. Redman CW, Sargent IL, Staff AC. IFPA Senior Award lecture: making
sense of pre-eclampsia – two placental causes of preeclampsia?
Placenta
2014;
35
(Suppl): S20–25.
25. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA,
Conrad KP. Altered global gene expression in first trimester placentas of
women destined to develop preeclampsia.
Placenta
2009;
30
(1): 15–24.
26. Pollheimer J, Fock V, Knofler M. Review: the ADAM metallopro-
teinases – novel regulators of trophoblast invasion?
Placenta
2014;
35
(Suppl): S57–63.
27. Ramesar SV, Mackraj I, Gathiram P, Moodley J. Sildenafil citrate
improves fetal outcomes in pregnant, L-NAME treated, Sprague-
Dawley rats.
Eur J Obstet Gynecol Reprod Biol
2010;
149
(1): 22–26.
28. Ramesar SV, Mackraj I, Gathiram P, Moodley J. Sildenafil citrate
decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley
rats.
Eur J Obstet Gynecol Reprod Biol
2011;
157
(2): 136–140.
29. Baijnath S, Soobryan N, Mackraj I, Gathiram P, Moodley J. The opti-
mization of a chronic nitric oxide synthase (NOS) inhibition model of
pre-eclampsia by evaluating physiological changes.
Eur J Obstet Gynecol
Reprod Biol
2014;
182
: 71–75.
30. Redman CW, Sargent IL. Latest advances in understanding preeclamp-
sia.
Science
2005;
308
(5728): 1592–1594.
31. Hung TH, Burton GJ. Hypoxia and reoxygenation: a possible mecha-
nism for placental oxidative stress in preeclampsia.
Taiwan J Obstet
Gynecol
2006;
45
(3): 189–200.
32. Yung HW, Atkinson D, Campion-Smith T, Olovsson M, Charnock-
Jones DS, Burton GJ. Differential activation of placental unfolded
protein response pathways implies heterogeneity in causation of early-
and late-onset pre-eclampsia.
J Pathol
2014;
234
(2): 262–276.
33. Hansson SR, Naav A, Erlandsson L. Oxidative stress in preeclampsia
and the role of free fetal hemoglobin.
Front Physiol
2014;
5
: 516.
34. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in
normal pregnancy and pre-eclampsia: an overview.
Reprod Biomed
Online
2006;
13
(5): 680–686.
35. Hawfield A, Freedman BI. Pre-eclampsia: the pivotal role of the placen-
ta in its pathophysiology and markers for early detection.
Therapeut Adv
Cardiovasc Dis
2009;
3
(1): 65–73.
36. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia:
pathophysiology, diagnosis, and management.
Vasc Health Risk Mgmt
2011;
7
: 467–474.
37. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial
growth factor acts as a survival factor for newly formed retinal vessels
and has implications for retinopathy of prematurity.
Nature Med
1995;
1
(10): 1024–1028.
38. Tal R. The role of hypoxia and hypoxia-inducible factor-1alpha in
preeclampsia pathogenesis.
Biol Reprod
2012;
87
(6): 134.
39. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North
RA. Longitudinal serum concentrations of placental growth factor:
evidence for abnormal placental angiogenesis in pathologic pregnancies.
Am J Obstet Gynecol
2003;
188
(1): 177–182.
40. Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta super-
family expression and actions in the endometrium and placenta.
Reproduction
2006;
132
(2): 217–232.
41. Fu G, Ye G, Nadeem L,
et al
. MicroRNA-376c impairs transforming
growth factor-beta and nodal signaling to promote trophoblast cell
proliferation and invasion.
Hypertension
2013;
61
(4): 864–872.
42. Bdolah Y, Karumanchi SA, Sachs BP. Recent advances in understand-
ing of preeclampsia.
Croatian Med J
2005;
46
(5): 728–736.
43. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial
growth factor (VEGF) and its receptors.
FASEB J
1999;
13
(1): 9–22.
44. Venkatesha S, Toporsian M, Lam C,
et al
. Soluble endoglin contributes
to the pathogenesis of preeclampsia.
Nature Med
2006;
12
(6): 642–649.
45. Bell MJ, Conley YP. A systematic review of endoglin gene expression in
preeclampsia.
Biol Res Nurs
2013;
15
(2): 129–136.
46. Bdolah Y, Sukhatme VP, Karumanchi SA. Angiogenic imbalance in
the pathophysiology of preeclampsia: newer insights.
Seminars Nephrol
2004;
24
(6): 548–556.
47. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia.
Seminars Nephrol
2011;
31
(1): 33–46.
48. Levine RJ, Maynard SE, Qian C,
et al
. Circulating angiogenic factors
and the risk of preeclampsia.
New Engl J Med
2004;
350
(7): 672–683.
49. Romero R, Nien JK, Espinoza J,
et al
. A longitudinal study of angio-
genic (placental growth factor) and anti-angiogenic (soluble endoglin
and soluble vascular endothelial growth factor receptor-1) factors in
normal pregnancy and patients destined to develop preeclampsia and
deliver a small for gestational age neonate. J
Matern Fetal Neonatal Med
2008;
21
(1): 9–23.
50. Maynard SE, Min JY, Merchan J,
et al.
Excess placental soluble fms-
like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunc-
tion, hypertension, and proteinuria in preeclampsia.
J Clin Invest
2003;
111
(5): 649–658.
51. Govender N, Naicker T, Moodley J. Maternal imbalance between pro-
angiogenic and anti-angiogenic factors in HIV-infected women with
pre-eclampsia.
Cardiovasc J Afr
2013;
24
(5): 174–179.
52. Govender L, Mackraj I, Gathiram P, Moodley J. The role of angiogenic,
anti-angiogenic and vasoactive factors in pre-eclamptic African women:
early- versus late-onset pre-eclampsia.
Cardiovasc J Afr
2012;
23
(3):
153–159.
53. Erez O, Romero R, Espinoza J,
et al.
The change in concentrations of
angiogenic and anti-angiogenic factors in maternal plasma between the
first and second trimesters in risk assessment for the subsequent devel-
opment of preeclampsia and small-for-gestational age.
J Matern Fetal
Neonatal Med
2008;
21
(5): 279–287.
54. Vatten LJ, Asvold BO, Eskild A. Angiogenic factors in maternal circula-
tion and preeclampsia with or without fetal growth restriction.
Acta
Obstet Gynecol Scandin
2012;
91
(12): 1388–1394.
55. Chaiworapongsa T, Romero R, Kim YM,
et al
. Plasma soluble vascular
endothelial growth factor receptor-1 concentration is elevated prior to
the clinical diagnosis of pre-eclampsia.
J Matern Fetal Neonatal Med
2005;
17
(1): 3–18.
56. Thadhani R, Kisner T, Hagmann H,
et al
. Pilot study of extracor-
poreal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.
Circulation
2011;
124
(8): 940–950.
57. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of
the immune system in preeclampsia.
Molec Aspects Med
2007;
28
(2):
192–209.
58. Szarka A, Rigo J, Jr, Lazar L, Beko G, Molvarec A. Circulating